Nurix Therapeutics Files Annual Report

Ticker: NRIX · Form: ARS · Filed: Mar 27, 2026 · CIK: 0001549595

Sentiment: neutral

Topics: annual-report, pharmaceuticals, sec-filing

TL;DR

Nurix Therapeutics filed its ARS for FY25 ending Nov 30, 2025. Check it for performance details.

AI Summary

Nurix Therapeutics, Inc. filed an Annual Report to Security Holders (ARS) on March 27, 2026, for the period ending November 30, 2025. The company, headquartered in Brisbane, CA, is involved in the Pharmaceutical Preparations industry. This filing provides a comprehensive overview of the company's performance and financial standing for the fiscal year.

Why It Matters

This filing provides shareholders and potential investors with crucial information regarding Nurix Therapeutics' financial health and operational performance over the past fiscal year.

Risk Assessment

Risk Level: low — This is a routine annual filing providing historical information, not indicating new risks.

Key Numbers

Key Players & Entities

FAQ

What is the CIK number for Nurix Therapeutics, Inc.?

The CIK number for Nurix Therapeutics, Inc. is 0001549595.

What is the primary business of Nurix Therapeutics, Inc. according to the filing?

Nurix Therapeutics, Inc. is primarily involved in Pharmaceutical Preparations (SIC code 2834).

What is the state of incorporation for Nurix Therapeutics, Inc.?

Nurix Therapeutics, Inc. is incorporated in Delaware (DE).

What is the file number associated with this company's Act 34 filings?

The file number for Act 34 filings is 001-39398.

What is the size of the complete submission text file for this ARS filing?

The complete submission text file (0001140361-26-011505.txt) is 5541610 bytes.

Filing Details

This Form ARS (Form ARS) was filed with the SEC on March 27, 2026 regarding Nurix Therapeutics, Inc. (NRIX).

View full filing on EDGAR

View Full Filing

View this ARS filing on SEC EDGAR

View on Read The Filing